Jasmohan Bajaj
LightNews LightNews
banner
jasmohanbajaj.bsky.social
Jasmohan Bajaj
@jasmohanbajaj.bsky.social
800 followers 390 following 11 posts
Liver specialist at Virginia Commonwealth University and Richmond VAMC . Interested in the brain liver gut axis. Co-EIC of Am J Gastro. Posts are personal.
Posts Replies Media Videos
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database
Barritt, et al.

📕 bit.ly/4kQDarW
June 20, 2025 at 11:00 AM
jasmohanbajaj.bsky.social
It's finally here! Consensus #ACLF & #cirrhosis organ failure definitions. ⤵️
pubmed.ncbi.nlm.nih.gov/40499736/
Why? We need to speak the same language re #ACLF
How? Multi-country consensus panels
Result? Harmonized definitions &  research agenda @aasldnews.bsky.social @easlnews.bsky.social
June 16, 2025 at 6:16 PM
Reposted by Jasmohan Bajaj
esgvh.bsky.social
Amazing panel discussions at the end of the EASL-ESCMID session at #EASLCongress 2025

#AMR, #liver, #cirrhosis

@easlnews.bsky.social
@escmid.bsky.social
@esgvh.bsky.social
@oana-sandulescu.bsky.social
@jasmohanbajaj.bsky.social
May 10, 2025 at 9:15 AM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In the #RedJournal:

Supplement — Demystifying Carbohydrate Maldigestion: A Clinical Review
Brooks D. Cash, MD, FACG; Daksesh Patel, DO & Kate Scarlata, MPH, RDN

📕 bit.ly/3GhUN4q
@katescarlata.bsky.social @jasmohanbajaj.bsky.social
April 20, 2025 at 1:00 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
Explore the April issue of the #RedJournal!

Featuring the new ⭐ ACG Guideline on Gastric Premalignant Conditions and ⭐ US Multi-Society Task Force on CRC consensus recommendations on bowel prep for colonoscopy.

📕 bit.ly/AmJGastro
@jasmohanbajaj.bsky.social
April 7, 2025 at 11:00 AM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In the 📕#RedJournal:

Timing of Direct Oral Anticoagulants Resumption Following Colorectal Endoscopic Submucosal Dissection: A Nationwide Study in Japan
Ichita, et al.

👉 bit.ly/4iRPbvM
March 24, 2025 at 4:00 PM
jasmohanbajaj.bsky.social
Recent study:⬆️ #daptomycin resist w #rifaximin.
But does this impact outcomes in #cirrhosis?
In VA & TriNetX we found no impact of rifaximin on dapt users on
🔑30-day mortality
🔑LT
🔑sepsis dev
🔑linezolid use
✅ @amergastroassn.bsky.social ➡️ pubmed.ncbi.nlm.nih.gov/40122471/ @absteward.bsky.social
March 24, 2025 at 1:27 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In the 📕#RedJournal:

The Red Section: Guidelines in Practice — Alcohol-Associated Liver Disease
Loretta L. Jophlin, MD, PhD*; Ashwani K. Singal, MD, MS, FACG* & Vijay H. Shah, MD, FACG

👉 bit.ly/4kPSMwk
@jasmohanbajaj.bsky.social
March 21, 2025 at 8:46 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In #CTGjournal:

Secondary SBP Prophylaxis is Associated with a Higher Rate of Non-SBP Infections in Two US-based National Cirrhosis Cohorts
Silvey, et al.

➡️ bit.ly/428BEKH
@jasmohanbajaj.bsky.social
March 15, 2025 at 6:23 PM
Reposted by Jasmohan Bajaj
anandvkulkarni.bsky.social
After five decades, steroid dosing in AAH is revisited: Tapered prednisolone proves superior in reducing infections.
#STASH trial @jasmohanbajaj.bsky.social @juanpabloarab.bsky.social @ebtapper.bsky.social @tonybreu.bsky.social
@blaneymd.medsky.social
journals.lww.com/ajg/abstract... #liversky
Infections in Standard or Tapered Dose of Prednisolone for... : Official journal of the American College of Gastroenterology | ACG
mary objective was to assess the incidence of infection by day 90. The key secondary objectives were the incidence of mortality, acute kidney injury (AKI), readmissions rate and adverse events. Metho...
journals.lww.com
March 13, 2025 at 5:12 PM
jasmohanbajaj.bsky.social
Unnecessary #antibiotics: #SBP prophylaxis in #cirrhosis ⬆️ #SBP & other infections! Esp #UTIs w similar🦠
latest from VA & Trinetx ⤵️
pubmed.ncbi.nlm.nih.gov/40062879/
50% of US ❌use SBPProph..should we all follow & ⬇️ #AMR?
@absteward.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social
March 11, 2025 at 12:01 AM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
Explore the March issue of The American Journal of #Gastroenterology!

📕 bit.ly/AmJGastro

@jasmohanbajaj.bsky.social @andrewmmoon.bsky.social
March 7, 2025 at 11:11 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
Dedicated to #ColorectalCancerScreening!

ACG's Board of Trustees under the leadership of President Dr. @amyoxentenkomd.bsky.social

These visionary leaders ensure ACG aligns its actions & priorities with its mission & vision

#ColorectalCancerAwarenessMonth #DressinBlueDay #ACGfamily #GastroSky
March 7, 2025 at 9:15 PM
jasmohanbajaj.bsky.social
Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social
March 2, 2025 at 2:30 PM
Reposted by Jasmohan Bajaj
insight.jci.org
ASCI member @jasmohanbajaj.bsky.social et al. show that fecal transplant ameliorates a source of cirrhosis progression.
JCI Insight - Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with FMT
Research LetterIn-Press PreviewHepatologyMicrobiology Open Access | 10.1172/jci.insight.186649
buff.ly
February 27, 2025 at 4:13 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In the 📕#RedJournal:

Update on Newly Federal Drug Administration-Approved Drug, Resmetirom: A Practical Perspective
A. Sidney Barritt, IV, MD, MSCR, FACG & Jonathan G. Stine, MD, MSc

👉 bit.ly/438oCOq

@sidbarritt4.bsky.social @jonathanstinemd.bsky.social
February 22, 2025 at 4:00 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
In the 📕#RedJournal:

The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites
Wong, et al.

👉 bit.ly/3QsoPnM
@jasmohanbajaj.bsky.social
February 21, 2025 at 7:52 PM
Reposted by Jasmohan Bajaj
prebeiro.bsky.social
Please check out this powerful statement re: #NIH by @kerialthoff.bsky.social :

🎥: www.instagram.com/reel/DF3kmec...

Then go here to check out the impact for *your* state:

💰: www.unitedformedicalresearch.org/nih-in-your-...

& Contact your US Sen.s/Rep.!:

☎️ : www.usa.gov/elected-offi...
NIH In Your State - United For Medical Research
Select a state on the map to see the impact of NIH funding across America.
www.unitedformedicalresearch.org
February 10, 2025 at 2:29 AM
Reposted by Jasmohan Bajaj
andrewmmoon.bsky.social
Metabolic risk factors are increasingly important drivers of primary liver cancer but.... it's complicated

Joseph Ahn lays out the power and perils of Global Burden of Disease data in this editorial in @amcollegegastro.bsky.social #AJG editorial

journals.lww.com/ajg/fulltext...

#GISky #LiverSky
A Global Perspective on Metabolically Driven Primary Liver... : Official journal of the American College of Gastroenterology | ACG
An abstract is unavailable.
journals.lww.com
February 10, 2025 at 2:07 PM
jasmohanbajaj.bsky.social
🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
February 5, 2025 at 1:43 PM
Reposted by Jasmohan Bajaj
docjonesy.bsky.social
Wait. ONE lousy trial is the major reason for spontaneous bacterial peritonitis prophylaxis?! Thanks to @paulsaxmd.bsky.social for this!

#IDSky #Medsky

academic.oup.com/cid/advance-...
Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: First, Do No Harm
Abstract. Antibiotic prophylaxis for spontaneous bacterial peritonitis (SBPPr) in patients with cirrhosis has been considered standard of care since the 19
academic.oup.com
February 4, 2025 at 9:43 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
The February Issue of The American Journal of #Gastroenterology is now available!

Explore this month's articles, including the new joint ACG-@asgeendo.bsky.social Quality Indicators for Upper GI Endoscopy!

📕bit.ly/AmJGastro
@jasmohanbajaj.bsky.social
February 4, 2025 at 7:43 PM
jasmohanbajaj.bsky.social
🙏 for highlighting our commentary @cidjournal.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
drtimothyli.bsky.social Timothy Li @drtimothyli.bsky.social · Feb 3
Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis

➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit

doi.org/10.1093/cid/...

#IDSky
February 3, 2025 at 3:53 PM
Reposted by Jasmohan Bajaj
amcollegegastro.bsky.social
ACG is proud to be hosting a summit on AI in GI, covering responsible, practical, and sustainable applications to improve clinical practice and patient outcomes.

Thanks to our many experts and innovators for helping shape the future of AI in our field! #AIinGI #GastroSky
January 24, 2025 at 9:54 PM
jasmohanbajaj.bsky.social
Pts w #Hepaticencephalopathy get a raw deal for #Livertransplant. Does MELD3.0 help?
🔑 we need to do more!
In @varesearch.bsky.social #cirrhosis pts @amcollegegastro.bsky.social
🔑inpt HE adds >4-5 MELD3.0 points for 90D & 6-7 for 1Y mortality
🔑HE needs priority!⤵️
pubmed.ncbi.nlm.nih.gov/39836914/
January 23, 2025 at 3:39 AM